The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome

Limited evidence exists to guide the management of recurrent thrombosis occurring despite therapeutic anticoagulation in patients with thrombotic antiphospholipid syndrome (APS). In this case series, fondaparinux, with or without an antiplatelet agent, provided an effective and safe option in three...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayar, Zara, Burke, Shoshana, Mittal, Prabal, Cohen, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580031/
https://www.ncbi.nlm.nih.gov/pubmed/36074077
http://dx.doi.org/10.1177/09612033221122147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580031/
https://www.ncbi.nlm.nih.gov/pubmed/36074077
http://dx.doi.org/10.1177/09612033221122147

Ejemplares similares